“As of today, we see no cause for concern regarding the competitive dynamics versus the market leaders... We really will need to see the data.”

 “Demand for anti-obesity drugs like Zepbound and Wegovy is so insatiable that Bloomberg Intelligence’s estimate for $80 billion in annual sales by 2030 is now looking conservative.”

 “A price-to-earnings ratio of over 20 had left the index 'nearly priced to perfection.' Therefore when a company disappoints, prices are likely to readjust sharply lower.”

 “I’m seeing an intolerance for the ‘we need to be patient’ conversation. The ‘wait and see, this is going to take time’ — investors don’t seem to have a lot of patience for that.”

 “All it takes is one large company like Eli Lilly to do it and then more risk-averse companies follow suit... Pharma groups were realising that 'the best way to convert customers is through patient portals where they can act as a consumer in medicine.'”